Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+8.45%
-1.84%
-0.49%
+0.15%
+11.08%
BBLG
Bone Biologics Corp
$4.03
Chart
$0.69 (+484.06%)
$0.84 (+379.76%)
$0.84 (+379.76%)
$1.1 (+266.36%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+8.45%
-1.84%
-0.49%
+0.15%
+11.08%
BBLG
Bone Biologics Corp
Current Price
$4.03
Buy
Login to view Bone Biologics Corp (BBLG) recommendation from the last 90 days from financial news and social media.
Chart
$0.69 (+484.06%)
$0.84 (+379.76%)
$0.84 (+379.76%)
$1.1 (+266.36%)
BBLG Latest Analysis
Bone Biologics Prices $5 Mln Public Offering With Warrants At $4 Per Share . (RTTNews) - Bone Biologics Corporation (BBLG) a developer of orthobiologic products for spine fusion has priced a public offering of 1250000 shares of common stock Series D warrants and Series E short-term warrants each exercisable for one common share at $4.00 per share.
Fri Jun 27, 2025
Why Is Bone Biologics Stock Surging On Friday?. ) stock is trading higher on Friday with a session volume of 17.22 million compared to the average volume of 38.795K .The company filed a patent application with the United States Patent and Trademark Office (USPTO) for its .Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures. It additionally has rights to trauma and osteoporosis applications.The patent application is
Fri Jun 27, 2025
BBLG Moves Toward Commercialization. By Bone Biologics (NASDAQ:BBLG) is a company developing products for the spine fusion market and is entering an exciting and crucial time period as human trials have begun and results should be available at least preliminary data in the coming year. Given the preclinical studies that weve reported on extensively we are optimistic that exciting results will be forthcoming that will positively impact the lives of thousands of spinal injury patients.In order to
Fri Jun 27, 2025
Bone Biologics prices $5M public offering with warrants. shares up 45%.
Fri Jun 27, 2025
Bone Biologics regains Nasdaq compliance with minimum bid price rule. shares down.
Thu Jun 26, 2025
BBLG Splits to Advance. By Bone Biologics (NASDAQ:BBLG) is a company developing products for spine fusion market and is entering an exciting and crucial time period as human trials have begun and results should be available at least preliminary data in the coming year. Given the preclinical studies that weve reported on extensively we are optimistic that exciting results will be forthcoming that will positively impact the lives of thousands of spinal injury patients.In order to continue the test
Wed Jun 11, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
BBLG Stock trends
BBLG Stock performance
BBLG Stock analysis
BBLG investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings